Overview
BLRX market data
Price History
BLRX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.00 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.65 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -171.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.10 – $2.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $39.3M · P/B 0.77 · P/S 11.17.
Company News
BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In OctoberBenzinga · Jul 20, 2026, 11:07 AM
BioLineRx And Hemispherian Announce New Preclinical Data Showing Strong Synergy Between GLIX1 And PARP Inhibitors In Patient-Derived Xenograft Model Of Ovarian CancerBenzinga · Jul 8, 2026, 11:15 AM
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsightGlobenewswire Inc · Jun 16, 2026, 5:15 PM
BioLineRx (BLRX) Q1 2026 Earnings TranscriptThe Motley Fool · May 29, 2026, 7:15 PM
BioLine Rx Q1 Sales $477.000K Beat $343.000K EstimateBenzinga · May 27, 2026, 11:02 AM
BioLineRx And Hemispherian Announce Two Abstracts Featuring GLIX1 Will Be Published At ASCO 2026 Annual MeetingBenzinga · May 22, 2026, 11:10 AM
BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal ModelsBenzinga · May 19, 2026, 10:30 PM
BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade GliomasBenzinga · May 19, 2026, 11:05 AM